Highlights From AACR IO 2026: Breaching the Tumor Microenvironment Fortress With New CAR T and Chimeras
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical...
The relationship between cigarette smoking and lung cancer was first brought to the public’s attention more than 50 years...
The San Antonio Breast Cancer Symposium (SABCS), which marks its 40th anniversary this year, has become the world's premier...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris)...
Kent Osborne, MD, a codirector of SABCS, wrote a guest post for Cancer Research Catalyst in 2015 that details...
Next to skin cancer, prostate cancer is the most diagnosed cancer among men in the United States. Data from...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing...
In the fall issue, Cancer Today had the honor of highlighting two women whose cancer diagnoses led them to...
Pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent, according to statistics...